A Phase I Study of Alemtuzumab for Therapy of Steroid-Refractory Chronic Graft-versus-Host Disease

Steroid-refractory chronic graft-versus-host disease (cGvHD) carries a poor prognosis with no agreed-upon algorithm for treatment. Since both B and T cells contribute to the pathophysiology of cGvHD, we conducted a Phase 1 study in subjects with steroid-refractory cGvHD using the anti-CD52 antibody...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Nikiforow, Sarah, Kim, Haesook T., Bindra, Bhavjot, McDonough, Sean, Glotzbecker, Brett, Armand, Philippe, Koreth, John, Ho, Vincent T., Alyea, Edwin P., Blazar, Bruce R., Ritz, Jerome, Soiffer, Robert J., Antin, Joseph H., Cutler, Corey S.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2013
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC3642980/
https://ncbi.nlm.nih.gov/pubmed/23416855
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bbmt.2013.02.009
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares